RECHALLENGE of SUNITINIB in
pNETS
GETNE1510:
RESUNET
A prospective, multi-center, open label, exploratory phase II study evaluating the efficacy and safety of the
rechallenge of sunitinib in advanced pancreatic neuroendocrine tumors
•
pNETs after progression to prior
sunitinib therapy
•
No more than two systemic
therapies between both
administrations of sunitinib
•
G1/G2
N = 36
SUNITINIB 37.5 mg qd
Primary endpoint:
Progression-free survival rate at 6 months (RECIST 1.1)
Main secondary endpoints:
Safety, mPFS, mOS, biomarkers
